Regenxbio Inc (RGNX)
8.76
-0.03
(-0.34%)
USD |
NASDAQ |
Nov 04, 16:00
8.765
0.00 (0.00%)
After-Hours: 20:00
Regenxbio Cash from Investing (Quarterly): -0.268M for June 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -0.268M |
| March 31, 2024 | 13.18M |
| December 31, 2023 | 33.97M |
| September 30, 2023 | 38.66M |
| June 30, 2023 | 55.22M |
| March 31, 2023 | 63.09M |
| December 31, 2022 | 26.70M |
| September 30, 2022 | 53.04M |
| June 30, 2022 | -1.081M |
| March 31, 2022 | -90.59M |
| December 31, 2021 | -216.36M |
| September 30, 2021 | 16.10M |
| June 30, 2021 | 7.799M |
| March 31, 2021 | -214.18M |
| December 31, 2020 | 11.57M |
| September 30, 2020 | 34.00M |
| June 30, 2020 | 44.48M |
| March 31, 2020 | 32.71M |
| December 31, 2019 | 14.15M |
| Date | Value |
|---|---|
| September 30, 2019 | 52.27M |
| June 30, 2019 | 21.67M |
| March 31, 2019 | 5.461M |
| December 31, 2018 | -67.18M |
| September 30, 2018 | -136.72M |
| June 30, 2018 | -38.37M |
| March 31, 2018 | -37.09M |
| December 31, 2017 | -1.143M |
| September 30, 2017 | 18.76M |
| June 30, 2017 | -25.58M |
| March 31, 2017 | 3.163M |
| December 31, 2016 | 17.44M |
| September 30, 2016 | 9.799M |
| June 30, 2016 | 2.893M |
| March 31, 2016 | -10.74M |
| December 31, 2015 | -144.34M |
| September 30, 2015 | -19.14M |
| June 30, 2015 | -0.209M |
| March 31, 2015 | -0.106M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-216.36M
Minimum
Dec 2021
63.09M
Maximum
Mar 2023
-4.095M
Average
16.10M
Median
Sep 2021
Cash from Investing (Quarterly) Benchmarks
| Sarepta Therapeutics Inc | -98.53M |
| Catalyst Pharmaceuticals Inc | -0.01M |
| Vertex Pharmaceuticals Inc | -463.70M |
| Edgewise Therapeutics Inc | 37.37M |
| Entrada Therapeutics Inc | -24.38M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -45.50M |
| Cash from Financing (Quarterly) | -9.445M |
| Free Cash Flow | -194.72M |
| Free Cash Flow Per Share (Quarterly) | -0.9085 |
| Free Cash Flow to Equity (Quarterly) | -45.97M |
| Free Cash Flow Yield | -48.25% |